Cellectar’s Survival Battle: Regulatory Wins Clash With Financial Strain

Cellectar Biosciences finds itself navigating turbulent market conditions as its shares experience significant volatility. The biopharmaceutical company faces a complex landscape where promising regulatory advancements for its lead cancer therapeutic are counterbalanced by precarious financial metrics and substantial selling pressure from investors.

A concerning trend has emerged in Cellectar’s trading patterns. As of November 14th, short interest reached 33.84%, indicating nearly one out of every three traded shares represented a bet against the company. This substantial bearish positioning highlights deep-seated market concerns despite clinical progress. Recent price action underscores this tension: after jumping 5.14% to $3.07 on November 18th, the equity retreated to approximately $2.86 in subsequent trading. Technical indicators currently point to Read more...